Zimmer Biomet Holdings Inc (NYSE:ZBH) Director Michael W. Michelson purchased 2,085 shares of the firm’s stock in a transaction that occurred on Friday, February 8th. The stock was bought at an average price of $119.69 per share, for a total transaction of $249,553.65. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Shares of Zimmer Biomet stock traded up $1.65 on Monday, reaching $122.23. 2,094,447 shares of the stock were exchanged, compared to its average volume of 1,421,855. Zimmer Biomet Holdings Inc has a one year low of $96.99 and a one year high of $134.55. The company has a current ratio of 1.85, a quick ratio of 0.91 and a debt-to-equity ratio of 0.75. The company has a market cap of $24.60 billion, a PE ratio of 16.00, a price-to-earnings-growth ratio of 2.16 and a beta of 1.16.
Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Friday, February 1st. The medical equipment provider reported $2.18 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $2.18. Zimmer Biomet had a negative net margin of 4.78% and a positive return on equity of 13.17%. The company had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter in the prior year, the firm posted $2.10 EPS. The firm’s quarterly revenue was up .1% on a year-over-year basis. Research analysts forecast that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Thursday, January 31st. Stockholders of record on Friday, December 28th were issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. The ex-dividend date was Thursday, December 27th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 12.57%.
ZBH has been the topic of a number of research reports. Citigroup upgraded shares of Zimmer Biomet from a “neutral” rating to a “buy” rating and upped their price target for the company from $122.00 to $127.00 in a research note on Wednesday, January 2nd. Zacks Investment Research lowered shares of Zimmer Biomet from a “hold” rating to a “sell” rating in a research report on Wednesday, October 17th. JPMorgan Chase & Co. lowered shares of Zimmer Biomet from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $140.00 to $118.00 in a research report on Wednesday, December 19th. Deutsche Bank assumed coverage on shares of Zimmer Biomet in a research report on Wednesday, January 2nd. They set a “hold” rating and a $108.00 target price on the stock. Finally, Morgan Stanley decreased their target price on shares of Zimmer Biomet from $149.00 to $126.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 2nd. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating and twelve have assigned a buy rating to the company. Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $127.52.
Institutional investors have recently modified their holdings of the company. Town & Country Bank & Trust CO dba First Bankers Trust CO lifted its holdings in shares of Zimmer Biomet by 100.0% during the 4th quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 3,306 shares of the medical equipment provider’s stock worth $343,000 after acquiring an additional 1,653 shares during the period. Calamos Advisors LLC lifted its stake in Zimmer Biomet by 6.8% in the 3rd quarter. Calamos Advisors LLC now owns 36,675 shares of the medical equipment provider’s stock valued at $4,822,000 after purchasing an additional 2,322 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Zimmer Biomet by 9.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,595,444 shares of the medical equipment provider’s stock valued at $1,524,453,000 after purchasing an additional 1,033,717 shares during the last quarter. AXA lifted its stake in Zimmer Biomet by 2.0% in the 3rd quarter. AXA now owns 112,525 shares of the medical equipment provider’s stock valued at $14,793,000 after purchasing an additional 2,166 shares during the last quarter. Finally, Legacy Financial Advisors Inc. lifted its stake in Zimmer Biomet by 176.4% in the 4th quarter. Legacy Financial Advisors Inc. now owns 351 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 224 shares during the last quarter. 88.81% of the stock is owned by institutional investors.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
See Also: What is the downside to momentum investing?